Why Elanco Animal Health Incorporated (ELAN) stock moved
Elanco Animal Health Incorporated (ELAN) shares climbed 7.9% to $25.55 as of November 6, 2026, a significant gain from the prior close of $23.68. BestStocks flagged the session as a major change for ELAN. The move is tied to an earnings beat. Below, we break down what changed for ELAN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Earnings Beat
Elanco Animal Health Incorporated (ELAN) reported EPS of $0.27 vs. consensus estimate of $0.20, beating estimates by 33.1% on 2026-11-06. ELAN earnings scheduled for 2027-02-23.
What it means for Elanco Animal Health Incorporated investors
For Elanco Animal Health Incorporated investors, the balance of recent signals points to a bullish shift. On the constructive side: Earnings beat with positive market reaction; Strong 7.9% price move. Weighing against that: Elanco Animal Health Incorporated (ELAN) moved -9.27% from $24.38 to $22.12 on 2026-08-07; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $26.67, implying +4.4% upside from $25.55. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality medium (72/100). With earnings roughly 109 days out, the next report is the most likely near-term test of the move.
ELAN price reaction
ELAN last traded at $25.55, up $1.87 (+7.90%) from the previous close of $23.68. The session traded on 0.9× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $22.36 and $25.55, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Elanco Animal Health Incorporated (ELAN)
The consensus analyst price target on Elanco Animal Health Incorporated (ELAN) is $26.67, 4.4% above the recent $25.55. Over the past 90 days analysts logged 0 upgrades, 1 maintain, and 1 downgrade. Here is how the bullish and bearish cases on ELAN line up.
The bullish case
- Wall Street's consensus price target of $26.67 implies +4.4% upside from $25.55.
- The Street's most bullish target is $30.00 (+17.4%).
- Earnings beat with positive market reaction.
- Strong 7.9% price move.
- Positive price momentum.
The bearish case
- The most bearish analyst target is $24.00 (-6.1%).
- 1 analyst downgrade in the past 90 days, most recently Jefferies to Hold (2026-10-20).
- Elanco Animal Health Incorporated (ELAN) moved -9.27% from $24.38 to $22.12 on 2026-08-07.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 6, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ELAN
Frequently asked questions about ELAN
Why did Elanco Animal Health Incorporated (ELAN) stock move?
ELAN climbed 7.9% to $25.55. The move is associated with an earnings beat.
How much did ELAN stock rise?
ELAN gained 7.90% ($1.87) versus the prior close of $23.68, last trading at $25.55 on 0.9× average volume.
When is Elanco Animal Health Incorporated's next earnings date?
ELAN's next earnings report is estimated for 2027-02-23 — about 109 days away.
What is the analyst price target for ELAN?
The consensus analyst price target for ELAN is $26.67, about 4.4% above the current $25.55. Over the past 90 days, analysts recorded 0 upgrades, 1 maintain, and 1 downgrade.
How BestStocks tracks ELAN
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for ELAN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 6, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.